Back to today’s briefing

Story perspectives

Breakthrough Drug Halves Alzheimer's Risk, Funding Delays Loom

3/19/2025

36 3

Summary

Story summary

Researchers at Washington University have unveiled an experimental drug that could delay Alzheimer’s symptoms for those genetically predisposed. In a study of 22 participants, the drug demonstrated a remarkable 50% reduction in symptom onset risk over eight years. Yet, funding delays from the NIH cast a shadow on the future of this promising treatment.

1 of 1

Story summary

Researchers at Washington University have unveiled an experimental drug that could delay Alzheimer’s symptoms for those genetically predisposed. In a study of 22 participants, the drug demonstrated a remarkable 50% reduction in symptom onset risk over eight years. Yet, funding delays from the NIH cast a shadow on the future of this promising treatment.